The impact of elevation of CK serum levels in patients under statins treatment

• Grant number: 09/51040-7
• Support Opportunities: Regular Research Grants
• Start date: October 01, 2009
• End date: April 30, 2012
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Antonio de Padua Mansur
• Grantee: Antonio de Padua Mansur
• Host Institution: Instituto do Coração Professor Euryclides de Jesus Zerbini (INCOR). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Cardiovascular diseases (CVD) are the main causes of death in men and women of the Brazilian population. Since 1984, there has been observed a related mortality. Factors associated with this reduction include the better socioeconomic conditions, improved access to education and healthcare systems, and, also, to drug treatments. Amid the arsenal of drugs currently used, the statins proved to be the safest and effective for the CAD prevention and treatment, despite problems with therapeutic compliance in our population. The statins main side effects are increased liver enzymes, myopathy and, exceptionally, rhabdomyolysis. Some studies addressing such effects were limited to those individuals with very high CK values (greater than 1 OX the upper limit of normal (ULN)). However, reports about the clinical importance of smaller variations of CK are lacking, according to other authors. The use of statins may promote increases in total CK, as a result there is increased serum concentration of CKMB. Thus, it may lead to AMI related diagnostic errors and its implications on therapeutic and prognostic issues. This study aims to analyze the current levels of CKMB, troponin I and carbonic anhydrase type III in patients using statins, who have total CK levels greater than 1x ULN. The clinical characteristics and serum levels of cardiac markers of 600 consecutive outpatients under statins treatment, who have increased serum levels of total CK, will be evaluated, as well as its evolution in the three following months. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

NOGUEIRA, A.; ROGGERIO, A.; STRUNZ, C. M. C.; MANSUR, A. P.. Biochemical markers of muscle damage in women and men treated with statins. EUROPEAN HEART JOURNAL, v. 38, p. 1-pg., 2017-08-01. (09/51040-7)